Archive
Research
-
The New Rules of Leadership
October 1, 2026
Leadership is not just about making the call. It is about earning the confidence to make it. At FleishmanHillard we call this License to Lead: the stakeholder permission organisations earn to make difficult decisions, navigate uncertainty and adapt as circumstances change. In our 2026 UK License to Lead report, The New Rules of Leadership, we uncover that this permission has practical value: 89% of UK engaged consumers surveyed said a strong, positive reputation gives organisations...
-
The Patient Engagement Gap Your Competitors Are Closing
February 27, 2026
By Barry Sudbeck and Laura Musgrave Here’s a question more pharma executives are asking: does patient engagement deliver measurable value, or is it primarily reputational? It’s a fair question. In an era where pharmaceutical innovation must demonstrate its value not only through clinical efficacy but also through demonstrated patient relevance, the question is no longer ‘whether’ to engage patients – it’s whether that engagement translates into an advantage. New research from FleishmanHillard’s Global Health & Life Sciences group suggests it may. Released in recognition of Rare Disease Day, The Patient...